NCT05680558View on ClinicalTrials.gov

Photopheresis in Early-stage Mycosis Fungoides

PHASE2RecruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

May 8, 2021

Primary Completion Date

March 31, 2026

Study Completion Date

July 31, 2027

Conditions
Cutaneous T Cell LymphomaMycosis Fungoides
Interventions
DRUG

UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis

Extracorporeal Photopheresis (ECP)

DEVICE

THERAKOS® CELLEX photopheresis system

THERAKOS® CELLEX is an FDA-approved extra-corporeal photopheresis system

Trial Locations (1)

10032

RECRUITING

Herbert Irving Pavilion, New York

Sponsors

Collaborators (1)

Mallinckrodt, Inc.
All Listed Sponsors
collaborator

Mallinckrodt, Inc.

UNKNOWN

lead

Columbia University

OTHER

NCT05680558 - Photopheresis in Early-stage Mycosis Fungoides | Biotech Hunter | Biotech Hunter